Consensus Myriad Genetics, Inc.

Stocks

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:01 2026-06-18 EDT			5-day change	1st Jan Change
4.540 ^USD	+3.65%		+4.85%	-26.18%

06-02	Myriad Genetics, Inc. Announces Appointment of Raj Jampa to Chief Technology Officer, Effective June 1, 2026	CI
05-27	Myriad Genetics Highlights Data Demonstrating Broad Clinical Utility of Precise Mrd Assay At 2026 Asco Annual Meeting	CI

Evolution of the Average Target: Myriad Genetics, Inc.

Evolution of the Target Price: Myriad Genetics, Inc.

Changes in Analyst Recommendations: Myriad Genetics, Inc.

247.QoG-lRZZ6B5sE6IId5rkrnQhSxoxOMw3Gbyk1yX1rM8.Dtvh_1cjpEYhXsx-OPeT4BVILSlncLRHU973sGmGyYZv1M_QUyymKDxH4w~b2fb8c4bcfbe933a856e1ddd9582b6b0

Analysts' recommendations: Myriad Genetics, Inc.

02-24	UBS Adjusts Price Target on Myriad Genetics to $6 From $8, Maintains Neutral Rating	MT
11-04	UBS Adjusts Myriad Genetics Price Target to $8 From $6, Maintains Neutral Rating	MT
25-08-07	UBS Adjusts Price Target on Myriad Genetics to $6 From $7, Maintains Neutral Rating	MT
25-08-06	Top Midday Gainers	MT
25-05-21	Myriad Genetics Shares Fall After Downgrade From Scotiabank	MT
25-05-21	Scotiabank Downgrades Myriad Genetics to Sector Perform From Sector Outperform, Adjusts Price Target to $6 From $20	MT
25-05-19	Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating	MT
25-05-08	Wolfe Research Downgrades Myriad Genetics to Peer Perform From Outperform	MT
25-05-07	UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating	MT
25-05-07	Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22	MT
25-04-09	Guggenheim Downgrades Myriad Genetics to Neutral From Buy	MT
25-03-12	Myriad Genetics Shares Rise After Upgrade From Piper Sandler	MT
25-03-12	Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50	MT
25-02-25	UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating	MT
24-12-09	Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30	MT
24-11-18	Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	MT
24-09-19	Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target	MT
24-09-19	Morgan Stanley Initiates Myriad Genetics at Equalweight	MT
24-08-28	Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target	MT
24-06-27	Scotiabank Initiates Myriad Genetics at Sector Outperform	MT
24-05-13	Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating	MT
24-01-29	Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating	MT
24-01-29	BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating	MT
23-12-19	Wells Fargo Initiates Myriad Genetics at Equalweight Rating With $20 Price Target	MT
23-12-13	Wolfe Research Initiates Myriad Genetics With Outperform Rating With $28 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MYRIAD GENETICS, INC.					+37.67%
	GUARDANT HEALTH, INC.					+7.59%
	BIOMÉRIEUX					+30.72%
	LANTHEUS HOLDINGS, INC.					+1.32%
	CARIS LIFE SCIENCES, INC.					+50.69%
	SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.					+54.07%
	10X GENOMICS, INC.					-22.76%
	DIASORIN S.P.A.					+7.16%
	AUTOBIO DIAGNOSTICS CO., LTD.					+29.28%
	Average					+21.75%
	Weighted average by Cap.					+17.74%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.540USD

Average target price

6.250USD

Spread / Average Target

+37.67%

High Price Target

10.00USD

Spread / Highest target

+120.26%

Low Price Target

4.000USD

Spread / Lowest Target

-11.89%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Scotiabank
Morgan Stanley
Wolfe Research
Wells Fargo Securities
Guggenheim
Piper Sandler
Leerink Partners
BofA Securities
Goldman Sachs
JPMorgan Chase
Morningstar
Jefferies & Co.
Stephens Inc.
Raymond James
SVB Securities LLC